Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker      Tax Corner NRI Centre Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Hindalco 148.45 0.27
Bhel 242.00 1.89
Ong Corp 400.05 1.97
Tata Stl 457.10 0.29
Tata Mot 519.45 3.54
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Wyeth Limited
Wyeth Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:500095NSE:WYETHBloomberg:WYH@INReuters:WLED.BO
Market Lot: 1Face Value: 10ISIN Demat: INE378A01012
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
25-NOV-13 The board of the directors of Pfizer (`Pfizer India) and Wyeth (Wyeth India) in their respective meetings have approved a proposal to merge Wyeth India with Pfizer India. 25-NOV-13 Pfizer, the research-based pharmaceutical company, announced that the board of directors has approved the payment of interim dividend of Rs 360 equity share of Rs 10 each (3600%) to the shareholders of the company. The said interim dividend will be paid on...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
Wyeth merger with Pfizer will increase long term value for all stakeholders: Aijaz Tabaccowalla  -IRIS 25-Nov-13
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)30-Sep-2009(6)31-Mar-2009 (12)31-Mar-2007 (12)
Net sales 2274.203826.602881.27
Other Income65.20199.8028.59
Total Income2339.404026.402909.87
Cost of goods sold1549.600.001869.20
OPBDIT789.804026.401040.67
PAT543.40996.70923.57
Gross Block--755.40
Equity capital227.20227.20227.20
EPS (Rs.)-43.8740.65
DPS (Rs.)--30.00
BV (Rs.)--112.97
P/E range (x)-7.93 - 11.6010.82 - 16.48
Debt / Equity (x)--0.01
Operating margin (% of OI)33.8100.035.8
Net margin (% of OI)23.224.831.7
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Level 6, Platina
Plot No C -59, G Block
Bandra ? Kurla Complex
Bandra (East)
Mumbai
Maharashtra-400 098
PHONE
(022) 2657 4000
FAX
(022) 2657 4100
 
Board of Directors
Board Meetings
Date Purpose
06-NOV-14 Quarterly Results
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer